Public Health Commons^™

Pharmacoeconomics Of Metastatic Colorectal Cancer Treatment With Targeted Therapies Guided By Companion Molecular Diagnostics, Luis E. Fernández-Garza, Hector Sánchez-Ibarra, Daniela Treviño-Sáenz, Hugo A. Barrera-Saldaña

Research Symposium

Background: To guide the treatment with monoclonal antibodies (MAbs) against the epidermal growth factor receptor (EGFR) of metastatic colorectal cancer (mCRC), the FDA recommends prior companion molecular diagnosis (CMDx). It initially recommended screening for mutations in exon 2 of the KRAS gene, and most recently to extend to screening to exons 2, 3, and 4 of KRAS and 2, 3, and 4 of NRAS genes; furthermore, to evaluate the BRAF exon 15 mutation status (including V600E). To date, no studies have been done to compare the cost-benefit of these different CMDXs.

Methods: We have compared the cost of treatment without …

The Role Of Community Pharmacists In The Provision Of Medication For Opioid Use Disorder Treatment In Rio Grande Valley, Tamara Al Rawwad, Ammar Kawaleet, Lydia Aguilera, Adrian Sandoval

Research Symposium

Background: The misuse of opioids, including prescription opioids, heroin, and fentanyl, has reached epidemic proportions in the US, resulting in more than 68,000 overdose deaths in 2020, and a total of $78.5 billion a year of economic burden. In response to this crisis, the US Department of Health and Human Services (DHHS) released a strategic plan to combat opioid abuse and misuse, recommending a multidisciplinary approach, including the inclusion of pharmacists in the efforts. The aim of this study is to examine pharmacists’ perception of their role in the provision of medication for opioid use disorders (MOUD) in addition to …